Vismodegib free base
To Order Contact us: lieven@wlsolutions.be
GDC-0449 (Vismodegib) |
||
| A3021-50 | 50 mg | EUR 150 |
|
Description: GDC-0449 (2-chloro-N-[4-chloro-3-pyridin-2-yl-phenyl]-4-methane-sulfonyl benzamide), discovered by high throughput screening of a small molecule compound library followed by subsequent optimization through medical chemistry, is a potent and selective inhibitor of hedgehog (Hh) signaling. |
||
GDC-0449 (Vismodegib) |
||
| A3021-500 | 500 mg | EUR 366 |
|
Description: GDC-0449 (2-chloro-N-[4-chloro-3-pyridin-2-yl-phenyl]-4-methane-sulfonyl benzamide), discovered by high throughput screening of a small molecule compound library followed by subsequent optimization through medical chemistry, is a potent and selective inhibitor of hedgehog (Hh) signaling. |
||
GDC-0449 (Vismodegib) |
||
| A3021-S | Evaluation Sample | EUR 97.2 |
|
Description: GDC-0449 (2-chloro-N-[4-chloro-3-pyridin-2-yl-phenyl]-4-methane-sulfonyl benzamide), discovered by high throughput screening of a small molecule compound library followed by subsequent optimization through medical chemistry, is a potent and selective inhibitor of hedgehog (Hh) signaling. |
||
Vismodegib (GDC-04491) |
||
| 27010 | 25 mg | EUR 90 |
|
Description: Vismodegib (GDC-0449) is a potent hedgehog (Hh) signaling pathway inhibitor. |
||
Vismodegib (GDC-04491) |
||
| 27015 | 50 mg | EUR 125 |
|
Description: Vismodegib (GDC-0449) is a potent hedgehog (Hh) signaling pathway inhibitor. |
||
Vismodegib (Hedgehog inhibitor) |
||
| SIH-565-25MG | 25 mg | EUR 205.2 |
|
Description: The substance Vismodegib is a hedgehog inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white powder which is May be dissolved in DMSO (200 mg/ml); or ethanol (10 mg/ml, warm). |
||
Vismodegib (Hedgehog inhibitor) |
||
| SIH-565-5MG | 5 mg | EUR 151.2 |
|
Description: The substance Vismodegib is a hedgehog inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white powder which is May be dissolved in DMSO (200 mg/ml); or ethanol (10 mg/ml, warm). |
||
TMB free base |
||
| TB0954 | 1g | EUR 85.06 |
FIPI (free base) |
||
| B2372-25 | each | EUR 757.2 |
FIPI (free base) |
||
| B2372-5 | each | EUR 235.2 |
THZ1 (Free base) |
||
| 9664-25 | each | EUR 1227.6 |
THZ1 (Free base) |
||
| 9664-5 | each | EUR 352.8 |
R406 (free base) |
||
| A5880-100 | 100 mg | EUR 1452 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-25 | 25 mg | EUR 616.8 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-5 | 5 mg | EUR 199.2 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-5.1 | 10 mM (in 1mL DMSO) | EUR 316.8 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-S | Evaluation Sample | EUR 97.2 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406(free base) |
||
| E1KS1533 | 2mg | EUR 625.2 |
R406 (free base) |
||
| HY-11108 | 10mM/1mL | EUR 277.2 |
YM158 (free base) |
||
| HY-U00355 | 1mg | EUR 2770.8 |
MCC950 (Free base) |
||
| B1031-1 | each | EUR 183.6 |
MCC950 (Free base) |
||
| B1031-5 | each | EUR 548.4 |
ITI214 (free base) |
||
| HY-12501 | 100mg | EUR 3531.6 |
PLX5622 (free base) |
||
| B2965-25 | 25 mg | EUR 903.6 |
PLX5622 (free base) |
||
| B2965-5 | 5 mg | EUR 272.4 |
AZD4547, Free Base |
||
| ADC-P-063 | unit | Ask for price |
AZD8055, Free Base |
||
| ADC-P-064 | unit | Ask for price |
AZD3839 (free base) |
||
| HY-13438 | 50mg | EUR 1216.8 |
Apatinib (Free base) |
||
| B1613-25 | each | EUR 496.8 |
Apatinib (Free base) |
||
| B1613-5 | each | EUR 170.4 |
Imatinib, Free base |
||
| 2141-100 | each | EUR 176.4 |
Imatinib, Free base |
||
| 2141-1000 | each | EUR 502.8 |
FR167344 free base |
||
| HY-100301 | 1mg | EUR 3164.4 |
FR183998 free base |
||
| HY-100302 | 1mg | EUR 1352.4 |
FR194738 free base |
||
| HY-100303 | 1mg | EUR 2388 |
Xylazine (free base) |
||
| Q-1445.0025 | 25.0g | EUR 385.2 |
|
Description: Sum Formula: C12H16N2S; CAS# [7361-61-7] |
||
Lapatinib, Free base |
||
| 2138-100 | each | EUR 464.4 |
Lapatinib, Free base |
||
| 2138-25 | each | EUR 229.2 |
Erlotinib, Free Base |
||
| 2048-100 | each | EUR 189.6 |
Erlotinib, Free Base |
||
| 2048-1000 | each | EUR 464.4 |
Sunitinib, Free base |
||
| 2097-100 | each | EUR 229.2 |
Sunitinib, Free base |
||
| 2097-1000 | each | EUR 601.2 |
Sunitinib, Free base |
||
| 2097-25 | each | EUR 138 |
Vatalanib, Free Base |
||
| 2026-25 | each | EUR 366 |
Vatalanib, Free Base |
||
| 2026-5 | each | EUR 151.2 |
LY2835219 free base |
||
| A3575-100 | 100 mg | EUR 686.4 |
|
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
||
LY2835219 free base |
||
| A3575-25 | 25 mg | EUR 309.6 |
|
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
||
LY2835219 free base |
||
| A3575-5 | 5 mg | EUR 170.4 |
|
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
||
Carubicin (Free base) |
||
| B1853-1 | each | EUR 183.6 |
Carubicin (Free base) |
||
| B1853-5 | each | EUR 548.4 |
Rucaparib (free base) |
||
| A8893-10 | 10 mg | EUR 240 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-200 | 200 mg | EUR 1243.2 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-5 | 5 mg | EUR 164.4 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-5.1 | 10 mM (in 1mL DMSO) | EUR 170.4 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-50 | 50 mg | EUR 547.2 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
RPR107393 free base |
||
| HY-100299 | 1mg | EUR 577.2 |
Vatalanib (free base) |
||
| HY-10203 | 5mg | EUR 142.8 |
Ripasudil free base |
||
| HY-15685A | 10mg | EUR 489.6 |
AS2863619 (free base) |
||
| HY-126675 | 5mg | EUR 1410 |
Linsitinib, Free base |
||
| 2294-25 | each | EUR 679.2 |
Linsitinib, Free base |
||
| 2294-5 | each | EUR 222 |
Tipifarnib, Free base |
||
| 2296-1 | each | EUR 170.4 |
Tipifarnib, Free base |
||
| 2296-5 | each | EUR 496.8 |
Nintedanib (free base) |
||
| GW5215-100 | 100 | EUR 274.7 |
Nintedanib (free base) |
||
| GW5215-25 | 25 | EUR 117.8 |
Terbinafine (Free base) |
||
| B2423-250 | each | EUR 248.4 |
Terbinafine (Free base) |
||
| B2423-50 | each | EUR 144 |
Ruxolitinib (free base) |
||
| 10-042 | 25 mg | EUR 418.2 |
|
Description: Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. It is investigated against the spread of the SARS-CoV-2 (COVID-19). |
||
Cyclopamine, Free Base |
||
| 27013 | 10 mg | EUR 130 |
|
Description: Cyclopamine inhibits activation of the Hedgehog response pathway by binding to and inhibiting the proto-oncogene Smoothened (SMO). The effects of oncogenic mutations that either activate SMO or inactivate the tumor suppressor Patched (Ptch) can be reversed by cyclopamine treatment. Cyclopamine has also been shown to induce apoptosis in colorectal adenoma cell lines, carcinoma-derived cell lines, and skin basal cell carcinomas and is being investigated as an anti-cancer drug. |
||
Ruxolitinib, Free base |
||
| 2139-100 | each | Ask for price |
Ruxolitinib, Free base |
||
| 2139-25 | each | EUR 639.6 |
Ruxolitinib, Free base |
||
| 2139-5 | each | EUR 248.4 |
Cyclopamine, Free Base |
||
| ADC-P-079 | unit | Ask for price |
Ixabepilone, Free Base |
||
| ADC-P-104 | unit | Ask for price |
Masupirdine (free base) |
||
| HY-109118 | 1mg | EUR 267.6 |
Ruxolitinib (free base) |
||
| GW2265-100 | 100 | EUR 404.9 |
Ruxolitinib (free base) |
||
| GW2265-25 | 25 | EUR 216.3 |
Ruxolitinib (free base) |
||
| GW2265-5 | 5 | EUR 116.1 |
GSK J4 free base |
||
| B5959-10 | 10 mg | EUR 447.6 |
|
Description: GSK J4 free base |
||
GSK J4 free base |
||
| B5959-50 | 50 mg | EUR 1437.6 |
|
Description: GSK J4 free base |
||
DOV-216,303 (Free Base) |
||
| HY-18332C | 10mM/1mL | EUR 590.4 |
GSK-J4 (Free base) |
||
| 2762-1 | each | EUR 144 |
GSK-J4 (Free base) |
||
| 2762-5 | each | EUR 314.4 |
AM-095 free base |
||
| A3167-10 | 10 mg | EUR 254.4 |
|
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1]. |
||
AM-095 free base |
||
| A3167-100 | 100 mg | EUR 964.8 |
|
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1]. |
||
AM-095 free base |
||
| A3167-200 | 200 mg | EUR 1382.4 |
|
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1]. |
||